查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1791749

非侵入性幽门螺旋桿菌检测的全球市场

Non-invasive Helicobacter Pylori Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球非侵入性幽门螺旋桿菌检测市场规模将达到 4.459 亿美元

全球非侵入性幽门螺旋桿菌检测市场规模预计在2024年为3.163亿美元，到2030年预计将达到4.459亿美元，在分析期间（2024-2030年）的复合年增长率为5.9%。血清学检测是本报告分析的细分市场之一，预计其复合年增长率为6.3%，到分析期结束时达到2.509亿美元。尿素呼气检测市场规模预计在分析期间的复合年增长率为4.8%。

美国市场规模估计为 8,320 万美元，中国市场预计复合年增长率为 5.8%

美国非侵入性幽门螺旋桿菌检测市场规模预计在2024年达到8,320万美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到7,180万美元，在2024-2030年的分析期内，复合年增长率为5.8%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为5.5%和5.0%。在欧洲，预计德国市场的复合年增长率为4.7%。

全球非侵入性幽门螺旋桿菌检测市场－主要趋势与驱动因素摘要

为什么非侵入性检测成为检测幽门螺旋桿菌的首选途径？

全球医疗保健在幽门螺旋桿菌 (H. pylori) 诊断方面正在发生重大转变，非侵入性检测方法正迅速取代传统的侵入性方法。从历史上看，内视镜检查和切片检查是识别这种胃病原体的黄金标准，但它会带来很大的不适感、高成本和操作风险，尤其是在无症状患者和儿科患者中。尿素呼气试验 (UBT)、粪便抗原试验 (SAT) 和血清学试验等非侵入性检测由于其简单、快速和患者友善性，现在已在临床和商业性广泛应用。这些检测无需镇静、侵入性样本采集或医院程序即可进行有效检体。尿素呼气试验尤其以其高准确性、快速性以及对初步诊断和治疗后后续观察的适用性而脱颖而出。此外，粪便抗原检测由于其可靠性和易于检体采集而被广泛采用，尤其是在小儿科。儘管血清学检测在根除后监测方面存在局限性，但在资源匮乏、价格可负担和便捷性至关重要的地区，它们仍被广泛应用。随着人们对胃炎、溃疡和胃癌日益增长的担忧，全球对胃肠道健康和早期检测的认识不断提高，极大地推动了这些非侵入性解决方案的普及。在医疗保健提供者转向价值导向医疗的时代，非侵入性幽门螺旋桿菌诊断技术将临床效率与患者依从性完美结合，重新定义了胃肠道疾病管理的标准。

检测技术的进步如何提高准确性和病患治疗效果？

技术进步在提高非侵入性幽门螺旋桿菌诊断的准确性、可及性和可扩展性方面发挥了核心作用。质谱法、免疫测量和标记碳同位素等创新技术显着提高了尿素呼气试验的敏感度和特异性，使临床医生能够非常自信地检测出活动性性行为感染。同样，基于单株抗体的粪便抗原检测的开发也提高了诊断准确性，最大限度地减少了假阴性，即使在低细菌负荷情况下也能提供可靠的结果。近年来，样品製备、转运介质和家用检测套组的进步进一步扩展了这些诊断方法的适用性，使其适用于社区和远端医疗模式。行动式呼吸检测装置和可携式分析仪也已进入市场，使乡村诊所、难民营和偏远医疗机构能够进行现场诊断。此外，将人工智慧主导的分析技术整合到实验室检测环境中，简化了工作流程并支援快速的结果解读，这对于高通量公共卫生实验室尤其有用。新兴企业正在探索使用非同位素感测器检测呼气生物标记物，预计将降低尿素呼吸检测的成本和复杂性。这些创新不仅提高了诊断质量，还能加速治疗决策，降低病情进展风险，并提高患者对后续治疗方案的依从性。随着如今医院外已有快速、准确的检测工具，幽门螺旋桿菌检测有望满足现代医疗保健对便利、快速和准确的期望。

公共卫生重点和筛检措施的变化是否会推动市场发展？

公共卫生重点的转变以及对早期胃肠道筛检的日益重视，是推动非侵入性幽门螺旋桿菌检测日益普及的关键因素。由于幽门螺旋桿菌与多种胃部疾病（包括消化性溃疡、慢性胃炎和胃癌）有关，因此早期发现和根除幽门螺旋桿菌是全球卫生策略的重点，尤其是在亚太地区、拉丁美洲和东欧等高发地区。在日本和韩国等国家，国家筛检计画已将非侵入性检测制度化，作为常规预防性筛检的一部分，从而显着降低了胃癌发病率。在西方国家，人们日益意识到未经治疗的幽门螺旋桿菌病菌感染与长期胃肠道併发症之间的关联，这促使全科医生即使在没有明显症状的情况下也建议进行筛检。 COVID-19 疫情进一步加速了向非侵入性诊断方法的转变，因为医疗保健系统正在寻求减少门诊程序并减轻医院基础设施压力的方法。非侵入性检测与这些修订后的通讯协定无缝衔接，支援在家采集样本和非接触式就诊。此外，医疗保险公司和支付方越来越认识到非侵入性早期检测的成本效益，并正在扩大呼气和粪便检测的报销范围。非政府组织和公共卫生机构也正在资助高负担和服务欠缺地区的低成本检测倡议，以提高可近性的公平性。随着这些计画的推广和成功，将非侵入性幽门螺旋桿菌检测作为预防性胃肠道护理基石的理由将变得更加引人注目。

哪些因素推动了非侵入性幽门螺旋桿菌检测市场的扩张？

非侵入性幽门螺旋桿菌检测市场的成长受到与技术创新、医疗保健服务趋势、不断变化的患者偏好和疾病负担动态相关的多种因素的驱动。在技术水准，诊断平台的快速进步使基于呼吸和粪便的测试更加可靠和高效，使其适合广泛的临床和家庭使用。这些平台越来越多地与数位健康工具相结合，实现结果追踪、自动警报以及患者和医疗保健提供者之间的无缝沟通。在临床方面，对门诊护理和早期诊断的日益增长的偏好促使医生选择非侵入性方法，以最大限度地降低风险、简化工作流程并加快治疗开始。最终用户的需求也受到消费者对肠道健康、食源性病原体以及未治疗感染疾病的长期风险的认识不断提高的影响。患者，尤其是年轻族群和那些能够获得数位健康资源的患者，正在积极寻求侵入性较小、更方便的检测选择。同时，由于卫生条件差、抗生素抗药性和饮食习惯改变等因素，幽门螺旋桿菌的盛行率不断上升，这推动了已开发市场和新兴市场对可扩展且经济高效的诊断方法的需求。医疗保健系统面临着降低成本和改善预防保健指标的压力，正在投资优先考虑非侵入性解决方案的筛检项目。最后，有利的监管条件和製药公司（尤其是销售用于根除治疗的抗生素的公司）的日益参与，正在推动透过将诊断与治疗通讯协定捆绑在一起的检测方法得到广泛采用。这些综合因素正在推动全球非侵入性幽门螺旋桿菌检测市场强劲且持续的成长。

部分

检测类型（血清学、尿素呼吸检测、粪便/粪便抗原检测）；检测方法（实验室检测、即时检测）；最终使用者（诊断实验室最终使用者、医院最终使用者、诊所最终使用者、其他最终使用者）

受访公司范例

  • Abbott Laboratories
  • Biohit Oyj
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Certest Biotec SL
  • Coris Bioconcept SPRL
  • DiaSorin SpA
  • Exalenz Bioscience Ltd.
  • Fujirebio Holdings, Inc.
  • Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Otsuka Holdings Co., Ltd.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Thermo Fisher Scientific Inc.

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP32372

Global Non-invasive Helicobacter Pylori Testing Market to Reach US$445.9 Million by 2030

The global market for Non-invasive Helicobacter Pylori Testing estimated at US$316.3 Million in the year 2024, is expected to reach US$445.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Serologic Test, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$250.9 Million by the end of the analysis period. Growth in the Urea Breath Test segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$83.2 Million While China is Forecast to Grow at 5.8% CAGR

The Non-invasive Helicobacter Pylori Testing market in the U.S. is estimated at US$83.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$71.8 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Non-Invasive Helicobacter Pylori Testing Market - Key Trends & Drivers Summarized

Why Is Non-Invasive Testing Emerging as the Preferred Route for Detecting H. Pylori?

The global healthcare landscape is witnessing a profound shift in the diagnosis of Helicobacter pylori (H. pylori) with non-invasive testing rapidly replacing traditional, invasive approaches. Historically, endoscopy with biopsy was the gold standard for identifying this gastric pathogen, but it came with considerable discomfort, higher costs, and procedural risks-especially for asymptomatic or pediatric patients. Non-invasive tests such as the urea breath test (UBT), stool antigen test (SAT), and serology are now gaining widespread clinical and commercial traction for their simplicity, speed, and patient-friendly nature. These methods allow for efficient detection without sedation, specimen collection through invasive means, or hospital-based procedures. The urea breath test, in particular, stands out due to its high accuracy, rapid turnaround time, and suitability for both initial diagnosis and post-treatment follow-up. Additionally, stool antigen tests have become widely adopted due to their reliability and ease of sample collection, especially in pediatric settings. Serological tests, while limited in post-eradication monitoring, are still widely used in low-resource settings where affordability and accessibility are paramount. The global increase in awareness of gastrointestinal health and early testing-fueled by growing concerns around gastritis, ulcers, and gastric cancers-is significantly propelling the adoption of these non-invasive solutions. In a world where healthcare providers are shifting toward value-based care, non-invasive H. pylori diagnostics offer a powerful blend of clinical efficiency and patient compliance, redefining standards in gastrointestinal disease management.

How Are Advancements in Testing Technology Enhancing Accuracy and Patient Outcomes?

Technological progress has played a central role in elevating the accuracy, accessibility, and scalability of non-invasive H. pylori diagnostics. Innovations in mass spectrometry, immunoassays, and labeled carbon isotopes have considerably improved the sensitivity and specificity of urea breath tests, allowing clinicians to detect active infections with exceptional confidence. Similarly, the development of monoclonal antibody-based stool antigen tests has enhanced diagnostic precision by minimizing false negatives and providing robust results even in low bacterial load scenarios. In recent years, advancements in sample preparation, transport media, and at-home testing kits have further expanded the reach of these diagnostics, making them more suitable for community and telehealth models. Mobile breath testing units and portable analyzers are also entering the market, enabling on-site diagnosis in rural clinics, refugee camps, and remote health settings. Furthermore, the integration of AI-driven analytics in lab-based testing environments is streamlining workflow and supporting quicker result interpretation, which is especially useful in high-throughput public health labs. Some emerging companies are even exploring breath biomarker detection using non-isotopic sensors, potentially reducing the cost and complexity of urea breath testing. Collectively, these innovations are not only raising the bar for diagnostic quality but also enabling faster treatment decisions, lowering disease progression risks, and improving patient adherence to follow-up regimens. With rapid and accurate tools now available outside of hospital walls, H. pylori testing is becoming more aligned with modern healthcare expectations-convenience, speed, and precision.

Are Shifting Public Health Priorities and Screening Initiatives Boosting Market Momentum?

Changing public health priorities and the growing emphasis on early gastrointestinal screening are key contributors to the increasing adoption of non-invasive H. pylori testing. With the bacterium implicated in a wide array of gastric disorders-including peptic ulcers, chronic gastritis, and gastric cancer-early detection and eradication have become focal points in global health strategies, especially in regions with high prevalence rates such as Asia-Pacific, Latin America, and Eastern Europe. National screening programs in countries like Japan and South Korea have already institutionalized non-invasive testing as part of routine preventive health check-ups, leading to measurable reductions in gastric cancer incidence. In Western countries, increased awareness about the link between untreated H. pylori infection and long-term gastrointestinal complications has spurred general practitioners to recommend screening even in the absence of overt symptoms. The COVID-19 pandemic has further accelerated the shift toward non-invasive diagnostics, as healthcare systems sought ways to minimize in-clinic procedures and reduce the burden on hospital infrastructure. Non-invasive tests fit seamlessly into these revised protocols, supporting home-based sample collection and contactless consultations. Additionally, health insurers and payers are increasingly recognizing the cost-effectiveness of early, non-invasive detection, and are extending reimbursement coverage to breath and stool-based tests. Non-governmental organizations and public health agencies are also funding low-cost testing initiatives in high-burden, underserved areas, reinforcing equity in access. As these programs expand and prove successful, the case for non-invasive H. pylori testing as a cornerstone of preventive gastrointestinal care becomes increasingly compelling.

What Factors Are Driving the Expansion of the Non-Invasive H. Pylori Testing Market?

The growth in the non-invasive Helicobacter pylori testing market is driven by several factors linked to technological innovation, healthcare delivery trends, changing patient preferences, and disease burden dynamics. At the technological level, rapid advancements in diagnostic platforms have led to more reliable and efficient breath and stool-based tests, making them suitable for widespread clinical and at-home use. These platforms are increasingly integrated with digital health tools, enabling result tracking, automated alerts, and seamless communication between patients and providers. On the clinical front, a growing preference for outpatient care and early diagnosis is motivating physicians to opt for non-invasive methods that minimize risk, streamline workflows, and accelerate treatment initiation. End-user demand is also being influenced by rising consumer awareness around gut health, foodborne pathogens, and the long-term risks of untreated infections. Patients, particularly in younger age groups and those with access to digital health resources, are actively seeking less invasive, more convenient testing options. In parallel, the increasing prevalence of H. pylori-driven by factors such as poor sanitation, antibiotic resistance, and changing dietary patterns-is fueling the need for scalable, cost-effective diagnostics across both developed and emerging markets. Healthcare systems under pressure to reduce costs and improve preventive care metrics are investing in screening programs that prioritize non-invasive solutions. Lastly, favorable regulatory landscapes and greater involvement from pharmaceutical companies-particularly those marketing antibiotics for eradication therapy-are encouraging widespread testing by bundling diagnostics with treatment protocols. These converging factors are ensuring strong, sustained growth in the non-invasive H. pylori testing market on a global scale.

SCOPE OF STUDY:

The report analyzes the Non-invasive Helicobacter Pylori Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Serologic Test, Urea Breath Test, Stool / Fecal Antigen Test); Method (Laboratory-based Test Method, Point of Care Test Method); End-Use (Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Biohit Oyj
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Certest Biotec S.L.
  • Coris Bioconcept SPRL
  • DiaSorin S.p.A.
  • Exalenz Bioscience Ltd.
  • Fujirebio Holdings, Inc.
  • Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Otsuka Holdings Co., Ltd.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Non-invasive Helicobacter Pylori Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Preference for Patient-Friendly Diagnostics Throws the Spotlight on Non-Invasive H. Pylori Testing Methods
    • Global Emphasis on Early Detection of Gastric Disorders Strengthens the Business Case for Non-Invasive Testing
    • Surge in Dyspepsia and Gastric Ulcer Cases Propels Growth Across Primary and Secondary Care Settings
    • Advancements in Urea Breath and Stool Antigen Tests Drive Accuracy and Broaden Clinical Adoption
    • Wider Integration into Preventive Health Check-Ups Expands the Addressable Market Opportunity
    • Government Screening Programs and Public Health Campaigns Accelerate Demand in High-Prevalence Regions
    • Shift Toward Decentralized and At-Home Testing Solutions Drives Adoption Among Convenience-Seeking Patients
    • Rise in Pediatric and Geriatric Gastrointestinal Care Spurs Demand for Gentler, Non-Invasive Test Options
    • Increased Awareness of H. Pylori's Role in Gastric Cancer Sustains Growth in Diagnostic Uptake
    • Healthcare Digitization and Lab Automation Strengthen Throughput and Efficiency of Non-Invasive Testing
    • Improved Sample Collection and Transport Technologies Drive Expansion in Remote and Low-Infrastructure Areas
    • Decline in Preference for Endoscopic Testing Creates Opportunities for Rapid, Low-Risk Alternatives
    • Pharmaceutical Alignment with Diagnostic Pathways Spurs Test-and-Treat Strategies Using Non-Invasive Methods
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-invasive Helicobacter Pylori Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Serologic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Serologic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Urea Breath Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Urea Breath Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Stool / Fecal Antigen Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Stool / Fecal Antigen Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Laboratory-based Test Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Laboratory-based Test Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Point of Care Test Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Point of Care Test Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION